VBI Vaccines Balance Sheet Health
Financial Health criteria checks 3/6
VBI Vaccines has a total shareholder equity of $7.5M and total debt of $50.8M, which brings its debt-to-equity ratio to 674.5%. Its total assets and total liabilities are $87.0M and $79.4M respectively.
Key information
674.5%
Debt to equity ratio
US$50.77m
Debt
Interest coverage ratio | n/a |
Cash | US$23.69m |
Equity | US$7.53m |
Total liabilities | US$79.42m |
Total assets | US$86.95m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LO9A's short term assets ($36.2M) do not cover its short term liabilities ($75.7M).
Long Term Liabilities: LO9A's short term assets ($36.2M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: LO9A's net debt to equity ratio (359.8%) is considered high.
Reducing Debt: LO9A's debt to equity ratio has increased from 14.3% to 674.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LO9A has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LO9A is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.